Semaglutide

Semaglutide

Semaglutide (NN9535) is an FDA-approved GLP-1 receptor agonist developed by Novo Nordisk, available as injectable Ozempic and Wegovy, oral Rybelsus, and certain compounded formulations studied in those settings across the SUSTAIN, STEP, and SELECT trial programs. Licensed practitioners looking to buy Semaglutide can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about Semaglutide and its research applications through the overview and FAQ section below.

What Is Semaglutide? Ozempic, Wegovy, Rybelsus & Compound Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist developed by Novo Nordisk. It is marketed in three branded products in the U.S., each with specific FDA-approved indications: Ozempic for adults with type 2 diabetes, Wegovy for chronic weight management and cardiovascular risk reduction, and Rybelsus for type 2 diabetes — with Rybelsus receiving a cardiovascular risk-reduction indication in adults at high cardiovascular risk in 2025.[6] As a metabolic peptide and incretin-based therapy, Semaglutide is widely studied for glycemic control, body weight reduction, and cardiovascular risk outcomes.[1],[2],[5]

A common question is whether Semaglutide is the same as Ozempic. Semaglutide is the active ingredient in both Ozempic and Wegovy, but the two products differ in approved indications, dose ceilings, and labeling.[5] Ozempic is approved for glycemic management in adults with type 2 diabetes and certain cardiovascular indications. Wegovy is approved for weight management and cardiovascular risk reduction.[3] Rybelsus contains the same active ingredient in oral tablet form.

Four Main Forms of Semaglutide

• Ozempic: Injectable formulation approved for type 2 diabetes, up to 2 mg weekly[5]
• Wegovy: Injectable formulation approved for weight management and cardiovascular risk reduction, up to 2.4 mg weekly[3]
• Rybelsus: Oral tablet for type 2 diabetes; received a cardiovascular risk-reduction indication in adults with type 2 diabetes at high cardiovascular risk in 2025, including those without a prior cardiovascular event[6]
• Compound Semaglutide: Not FDA-approved; may differ from branded products in salt form, excipients, manufacturing standards, and regulatory oversight — and became subject to additional legal restrictions after the FDA determined the shortage was resolved in February 2025[4]

On the topic of salt forms, regulatory agencies have distinguished between Semaglutide base and Semaglutide sodium, particularly in compounding contexts. Practitioners evaluating the compounding of Semaglutide and Tirzepatide should recognize that compounded products are not equivalent to branded formulations and carry different regulatory and quality control profiles.[4]

How Does Semaglutide Work? Mechanism of Action

Semaglutide is a pure GLP-1 receptor agonist.[5] It binds to and activates GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system, and does not activate GIP or glucagon receptors. This distinguishes it from Tirzepatide, which combines GLP-1 and GIP receptor agonism, and from Retatrutide, which adds glucagon receptor activation on top of both.

Its primary mechanisms include:

• Pancreas: Increases glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control in adults with type 2 diabetes[5]
• Brain/hypothalamus: Activates satiety pathways that reduce appetite and food intake, supporting its role as an adjunct to diet and exercise[5]
• Gastrointestinal tract: Slows gastric emptying, prolonging post-meal fullness and reducing postprandial glucose excursions[5]

Beyond these metabolic effects, Semaglutide has demonstrated cardiovascular benefits in large randomized trials. In SUSTAIN-6, Marso et al. (New England Journal of Medicine, 2016) reported a significant reduction in the rate of major adverse cardiovascular events among patients with type 2 diabetes and elevated cardiovascular risk.[1] The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) reported a significant reduction in major cardiovascular events among overweight and obese adults with established cardiovascular disease.[2]

Semaglutide for Weight Loss, Dosing & Safety

Semaglutide is supported by multiple large randomized trials across glycemic, weight, and cardiovascular outcomes. In the STEP-1 trial, Wilding et al. (New England Journal of Medicine, 2021) reported approximately 15% mean body weight reduction at 68 weeks among participants receiving Wegovy 2.4 mg weekly alongside lifestyle intervention.[2]

Semaglutide Dosing

Dosing should be individualized based on documented tolerability and the treatment context being evaluated.

Injectable Semaglutide (Ozempic/Wegovy)

• Initiation at 0.25 mg weekly
• Escalation to 0.5 mg, then 1 mg and 2 mg weekly (Ozempic)
• Up to 2.4 mg weekly (Wegovy); FDA later approved a 7.2 mg Wegovy HD dose in March 2026.
• Gradual titration over approximately 16–20 weeks

Oral Semaglutide / Semaglutide Tablets (Rybelsus)

• Initiation at 3 mg daily
• Escalation to 7 mg daily
• Maintenance up to 14 mg daily
• Taken fasting with no more than 120 mL of water, at least 30 minutes before food, beverages, or other medications[5]

Semaglutide Injection Administration

Semaglutide injection is administered subcutaneously into the abdomen, thigh, or upper arm once weekly. Injection site rotation is recommended to reduce local irritation. Storage guidance generally includes refrigeration at 2–8°C before first use, room-temperature stability for up to 56 days after opening, and protection from direct light per product labeling.[5]

Is Semaglutide Safe?

Semaglutide is supported by multiple large randomized trials across glycemic, weight, and cardiovascular outcomes, including the SUSTAIN, STEP, and SELECT programs.[1],[2] No therapy is universally appropriate, and individual assessment remains necessary.

Semaglutide Side Effects

The most commonly reported side effects include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort

These gastrointestinal effects are generally dose-dependent and most prominent during dose escalation.[5] Fatigue has been reported by some individuals, particularly during periods of GI adjustment and reduced caloric intake. Current evidence suggests fatigue is typically a secondary response rather than a direct pharmacological effect and tends to be transient.[5]

Additional class-level considerations include pancreatitis monitoring, gallbladder disease risk, and thyroid C-cell tumor warnings based on rodent studies not confirmed in humans.[5]

Legal Status of Semaglutide

As of June 2026, Semaglutide is marketed in the following branded products in the U.S., each with specific FDA-approved indications:[3],[5]

• Ozempic for type 2 diabetes
• Wegovy for chronic weight management and cardiovascular risk reduction
• Rybelsus for type 2 diabetes; received a cardiovascular risk-reduction indication in adults at high cardiovascular risk in 2025, including those without a prior cardiovascular event[6]

The FDA placed Semaglutide on its drug shortage list, which temporarily allowed compounding under shortage-related provisions. The FDA determined the shortage was resolved in February 2025. A grace period followed, but that window for compounding essentially copies ended afterward.[4] Compounded Semaglutide is not FDA-approved and may differ from branded products in formulation, quality control, and legal status. Regulatory guidance on compounding continues to evolve, and practitioners should verify the latest FDA communications before making any procurement decisions.

Practitioners operating in jurisdictions outside the U.S. should verify Semaglutide’s approval and reimbursement status through the relevant national regulatory authority, as policies vary by country. Athletes and practitioners subject to anti-doping requirements should verify current prohibited substance lists through the relevant governing body before use.

Semaglutide vs Tirzepatide

Semaglutide and Tirzepatide are both FDA-approved metabolic therapies with distinct mechanisms. Semaglutide is a pure GLP-1 receptor agonist, while Tirzepatide adds GIP receptor agonism, which may enhance insulin secretion and adipose tissue metabolism beyond GLP-1 alone. In the SURMOUNT-1 trial, Jastreboff et al. (New England Journal of Medicine, 2022) reported approximately 21% body weight reduction at the highest Tirzepatide dose, compared with approximately 15% in the STEP-1 Semaglutide trial.[2] These figures come from separate trials with different populations and designs and should not be read as a direct head-to-head comparison.

Semaglutide carries a longer clinical evidence record, with cardiovascular outcome data from SUSTAIN-6 and SELECT.[1],[2] Tirzepatide’s dual receptor mechanism shows greater weight-loss magnitude in available trial data, and its evidence base continues to grow. Practitioners comparing the two compounds can find sourcing and documentation guidance for both,  including information on how to buy Tirzepatide, through Medical Spa Rx’s professional support team.

Semaglutide vs Retatrutide

Semaglutide and Retatrutide represent different stages of development. Semaglutide is FDA-approved and backed by data from the SUSTAIN, STEP, and SELECT programs.[1],[2] Retatrutide remains investigational and combines GLP-1, GIP, and glucagon receptor agonism. In a Phase 2 study, Jastreboff et al. (New England Journal of Medicine, 2023) reported approximately 24% weight reduction at higher Retatrutide doses — a figure that comes from an early-phase trial and cannot be directly compared with STEP-1 data given differences in design, population, and development stage.

For practitioners tracking the investigational pipeline alongside established options, Retatrutide represents the next tier of receptor complexity, but without an approved protocol or long-term safety record. Procurement and research decisions should weigh evidence strength against regulatory status for each compound. Researchers who buy Retatrutide for investigational work will find it useful to compare it against Semaglutide’s approved profile when evaluating receptor mechanism and evidence maturity. Medical Spa Rx’s professional support team can provide sourcing guidance and documentation support for both compounds.

Where Can Practitioners Buy Semaglutide Online?

Practitioners looking to buy Semaglutide online should source exclusively from suppliers who provide verifiable purity documentation, LOT number traceability, and a certificate of analysis (COA). This is especially relevant given the regulatory changes that followed the FDA’s February 2025 determination that the Semaglutide shortage was resolved, which materially changed the compounding landscape.[4]

Semaglutide is available for purchase by qualified professionals only. Institutions and practitioners reviewing wholesale options are encouraged to confirm the regulatory and formulation status of any product before placing an order. Medical Spa Rx’s professional support team offers sourcing guidance and access to documentation support for licensed professionals evaluating their options. To learn more about verified suppliers or to request documentation, contact Medical Spa Rx’s professional support team directly.

FAQs

1. What is Semaglutide — is it the same as Ozempic?

Semaglutide (NN9535) is an FDA-approved GLP-1 receptor agonist developed by Novo Nordisk, marketed in three branded U.S. products.[5] Ozempic and Wegovy both contain Semaglutide as the active ingredient but have different approved indications and dose ceilings. Rybelsus is the oral tablet form and received a cardiovascular risk-reduction indication in adults at high cardiovascular risk in 2025.[6] Compounded Semaglutide differs in salt form and is not FDA-approved.[4]

2. How does Semaglutide work?

Semaglutide activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. It increases glucose-dependent insulin secretion, suppresses glucagon release, reduces appetite, and slows gastric emptying. Unlike Tirzepatide and Retatrutide, Semaglutide does not activate GIP or glucagon receptors.[5]

3. What is the Semaglutide dosing for weight loss?

Wegovy dosing typically begins at 0.25 mg weekly and escalates to 2.4 mg weekly over approximately 16–20 weeks.[3] Ozempic may reach 2 mg weekly for type 2 diabetes management. Oral Rybelsus ranges from 3 mg to 14 mg daily. Compounded Semaglutide protocols vary and are not FDA-approved.[4]

4. What are the Semaglutide side effects?

The most common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, generally most pronounced during dose escalation. Additional considerations include pancreatitis risk, gallbladder disease, and thyroid-related label warnings based on rodent findings not confirmed in humans.[5]

5. How does Semaglutide compare to Tirzepatide?

Semaglutide is a pure GLP-1 receptor agonist, while Tirzepatide combines GLP-1 and GIP receptor activation. Separate clinical trials reported approximately 15% mean weight loss with Semaglutide (STEP-1) and approximately 21% with Tirzepatide (SURMOUNT-1).[2] These are cross-trial figures, not head-to-head data. Both therapies are FDA-approved with established prescribing protocols.

6. Is Semaglutide legal — and what about compound Semaglutide?

Semaglutide is FDA-approved as Ozempic, Wegovy, and Rybelsus.[3],[5] The FDA placed Semaglutide on its drug shortage list, temporarily allowing compounding under shortage-related provisions. The FDA determined the shortage was resolved in February 2025, a grace period followed, and that window for compounding essentially copies ended afterward.[4] Following that determination, compounded copies became significantly more legally sensitive. Practitioners should verify current compounding guidance before making procurement decisions.

7. Where to buy Semaglutide?

Licensed professionals evaluating sourcing options should prioritize regulatory compliance, formulation verification, and purity documentation. When buying Semaglutide online, confirming the formulation status — branded versus compounded — is especially important given the regulatory changes since February 2025.[4] Professionals can also explore wholesale purchasing options that align with applicable regulations and quality standards. Medical Spa Rx’s professional support team can provide sourcing guidance and documentation support for those assessing qualified suppliers.

Sources

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
3. S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. FDA.gov. Published March 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
4. S. Food and Drug Administration. Compounding and FDA: Questions and answers — semaglutide shortage status. FDA.gov. Updated February 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
5. Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
6. Novo Nordisk. FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event. PR Newswire. Published October 2025. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-cv-risk-reduction-in-adults-with-type-2-diabetes-who-are-at-high-risk-including-those-who-have-not-had-a-prior-cv-event-302588005.html

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.